A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)

Trial Profile

A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNITE
  • Sponsors Orexigen Therapeutics
  • Most Recent Events

    • 06 Jan 2017 Results published in an Orexigen Therapeutics media release.
    • 27 Dec 2016 Results published in the Obesity (Silver Spring, Md.)
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top